Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: James J. Harding, Sarina Anne Piha-Paul, Ronak H. Shah, James M. Cleary, David I. Quinn, Irene Brana, Victor Moreno, Mitesh J. Borad, Sherene Loi, Iben Spanggaard, James M. Ford, Daniel DiPrimeo, Michael F. Berger, Lisa DeFazio Eli, Funda Meric-Bernstam, David B. Solit, Ghassan K. Abou-Alfa
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, University of Southern California, USC Norris Comprehensive Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Universitario Fundación Jiménez Díaz, Mayo Clinic Hospital, Peter MacCallum Cancer Centre, Copenhagen University Hospital, Rigshospitalet, Stanford Cancer Institute, Puma Biotechnology (United States)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281767361